Thyroid Gland Disorder Treatment Market by Disease Type (Hyperthyroidism and Hypothyroidism), Drug Type (Levothyroxine, Liothyronine, Propylthiouracil, Imidazole-based Compound, and Others), Route of Administration (Oral, Intravenous, and Others), and Distribution/Sales Channel (Wholesaler/Distributor, Retailer, Mail-order Pharmacy, and Others) - Global and Forecast up to 2027
The thyroid gland disorder treatment market refers to the market for products and therapies used in the management and treatment of thyroid gland disorders. The thyroid gland refers to a small butterfly-shaped gland situated in the front of the neck which produces hormones required for regulating several bodily functions. Thyroid disorders can occur when the thyroid gland produces too much hormone (hyperthyroidism) or too little hormone (hypothyroidism. Increasing Prevalence of Thyroid Disorders: Thyroid disorders, including hypothyroidism, hyperthyroidism, and thyroid nodules, are becoming more prevalent globally. Factors such as sedentary lifestyles, stress, environmental pollution, and dietary imbalances contribute to the rising incidence of thyroid gland disorders. As a result, there is a growing demand for diagnostic tests, medications, and treatment options, driving the market's growth. On the other hand, the factors such as negative impacts which cause lesser patient adherence and strict government regulations are likely to hamper the thyroid gland disorder treatment market growth. Thyroid Gland Disorder Treatment Market is likely to grow at a rate of 4.8% CAGR by 2027.
Thyroid Gland Disorder Treatment Market by Disease Type
Hypothyroidism
Hyperthyroidism
Thyroid Gland Disorder Treatment Market by Drug Type
Levothyroxine
Liothyronine
Propylthiouracil
Imidazole-based compounds
Thyroid Gland Disorder Treatment Market by Route Of Administration
Oral
Intravenous route
Thyroid Gland Disorder Treatment Market by Distribution Channel
Wholesaler/Distributor Retailer Mail-order Pharmacy Others
Retailer
Mail-Order Pharmacy
Thyroid Gland Disorder Treatment Market by Geography
North America
Europe
Asia Pacific
Rest of the World
Here is an overview of the key aspects of the thyroid gland disorder market:
Hypothyroidism Treatment: Hypothyroidism occurs when the thyroid gland doesn't produce enough thyroid hormone. The main treatment for hypothyroidism is hormone replacement therapy with synthetic thyroid hormone medication, typically levothyroxine. Levothyroxine is taken orally and helps restore the hormone levels in the body.
Hyperthyroidism Treatment: Hyperthyroidism occurs when the thyroid gland produces an excess of thyroid hormone. Treatment options for hyperthyroidism are medications, radioactive iodine therapy and surgery. Antithyroid medications, such as methimazole and propylthiouracil, can help reduce the production of thyroid hormone. Radioactive iodine therapy involves the administration of radioactive iodine, which destroys or shrinks the overactive thyroid cells. In few cases, surgical removal of all or part of the thyroid gland (thyroidectomy) may be required.
Diagnostic Tests: Various diagnostic tests are used to evaluate thyroid function and detect thyroid disorders. Blood tests, such as thyroid-stimulating hormone (TSH), free thyroxine (T4), and triiodothyronine (T3) tests, are commonly performed to assess hormone levels. Imaging techniques like ultrasound and nuclear medicine scans may be used to visualize the thyroid gland and detect abnormalities.
Market Trends: The thyroid gland disorder market is experiencing several trends. There is a growing focus on early detection and diagnosis of thyroid disorders through screening programs and increased awareness. Advances in diagnostic technologies are improving the accuracy and efficiency of thyroid function testing. Additionally, research is ongoing to develop targeted therapies for specific thyroid disorders, such as novel medications for hyperthyroidism and potential gene therapies for certain genetic thyroid disorders.
Thyroid Cancer Treatment: Thyroid cancer, though relatively rare, is another aspect of the thyroid gland disorder market. Treatment for thyroid cancer typically involves surgery to remove the cancerous thyroid tissue, followed by radioactive iodine therapy to destroy any remaining thyroid cells. In some cases, external beam radiation therapy and targeted therapies may be used to treat advanced or recurrent thyroid cancer.
The major leading companies of the thyroid gland disorder market are Abbott Laboratories, AbbVie Inc, Allergan Plc, GlaxoSmithKline plc, Lannett Company, Inc, Merck & Co. Inc, Mylan N.V, Novartis AG, Pfizer Inc, and RLC LABS, Inc
It's important to note that the treatment approach for thyroid gland disorders depends on the specific diagnosis, severity of symptoms, individual patient characteristics, and the guidance of healthcare professionals. Regular monitoring and follow-up with healthcare providers are crucial for optimizing treatment and managing thyroid gland disorders effectively.
An exclusive analysis of all key geographical regions is included in the report which determines the potential opportunities in these regions.
Detailed information about the attributes which are generating growth in the thyroid gland disorder treatment market in the forecast period.
An exact estimation of the thyroid gland disorder treatment market share and its contribution to the parent market is provided in the report.
Further profiles of key competitors and their dynamic strategies are also covered in the study.
Thyroid Gland Disorder Treatment Market by Disease Type
Hypothyroidism
Hyperthyroidism
Thyroid Gland Disorder Treatment Market by Drug Type
Levothyroxine
Liothyronine
Propylthiouracil
Imidazole-based compounds
Thyroid Gland Disorder Treatment Market by Route Of Administration
Oral
Intravenous route
Thyroid Gland Disorder Treatment Market by Distribution Channel
Wholesaler/Distributor Retailer Mail-order Pharmacy Others
Retailer
Mail-Order Pharmacy
Thyroid Gland Disorder Treatment Market by Geography
North America
Europe
Asia Pacific
Rest of the World
Here is an overview of the key aspects of the thyroid gland disorder market:
Hypothyroidism Treatment: Hypothyroidism occurs when the thyroid gland doesn't produce enough thyroid hormone. The main treatment for hypothyroidism is hormone replacement therapy with synthetic thyroid hormone medication, typically levothyroxine. Levothyroxine is taken orally and helps restore the hormone levels in the body.
Hyperthyroidism Treatment: Hyperthyroidism occurs when the thyroid gland produces an excess of thyroid hormone. Treatment options for hyperthyroidism are medications, radioactive iodine therapy and surgery. Antithyroid medications, such as methimazole and propylthiouracil, can help reduce the production of thyroid hormone. Radioactive iodine therapy involves the administration of radioactive iodine, which destroys or shrinks the overactive thyroid cells. In few cases, surgical removal of all or part of the thyroid gland (thyroidectomy) may be required.
Diagnostic Tests: Various diagnostic tests are used to evaluate thyroid function and detect thyroid disorders. Blood tests, such as thyroid-stimulating hormone (TSH), free thyroxine (T4), and triiodothyronine (T3) tests, are commonly performed to assess hormone levels. Imaging techniques like ultrasound and nuclear medicine scans may be used to visualize the thyroid gland and detect abnormalities.
Market Trends: The thyroid gland disorder market is experiencing several trends. There is a growing focus on early detection and diagnosis of thyroid disorders through screening programs and increased awareness. Advances in diagnostic technologies are improving the accuracy and efficiency of thyroid function testing. Additionally, research is ongoing to develop targeted therapies for specific thyroid disorders, such as novel medications for hyperthyroidism and potential gene therapies for certain genetic thyroid disorders.
Thyroid Cancer Treatment: Thyroid cancer, though relatively rare, is another aspect of the thyroid gland disorder market. Treatment for thyroid cancer typically involves surgery to remove the cancerous thyroid tissue, followed by radioactive iodine therapy to destroy any remaining thyroid cells. In some cases, external beam radiation therapy and targeted therapies may be used to treat advanced or recurrent thyroid cancer.
The major leading companies of the thyroid gland disorder market are Abbott Laboratories, AbbVie Inc, Allergan Plc, GlaxoSmithKline plc, Lannett Company, Inc, Merck & Co. Inc, Mylan N.V, Novartis AG, Pfizer Inc, and RLC LABS, Inc
It's important to note that the treatment approach for thyroid gland disorders depends on the specific diagnosis, severity of symptoms, individual patient characteristics, and the guidance of healthcare professionals. Regular monitoring and follow-up with healthcare providers are crucial for optimizing treatment and managing thyroid gland disorders effectively.
An exclusive analysis of all key geographical regions is included in the report which determines the potential opportunities in these regions.
Detailed information about the attributes which are generating growth in the thyroid gland disorder treatment market in the forecast period.
An exact estimation of the thyroid gland disorder treatment market share and its contribution to the parent market is provided in the report.
Further profiles of key competitors and their dynamic strategies are also covered in the study.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. DISEASE TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Hypothyroidism
5.3. Hyperthyroidism
6. DRUG TYPE: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Levothyroxine
6.3. Liothyronine
6.4. Propylthiouracil
6.5. Imidazole-based compounds
7. ROUTE OF ADMINISTRATION: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Oral
7.3. Intravenous route
8. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. Wholesaler/Distributor Retailer Mail-order Pharmacy Others
8.3. Retailer
8.4. Mail-Order Pharmacy
9. GEOGRAPHY: MARKET SIZE & ANALYSIS
9.1. Overview
9.2. North America
9.3. Europe
9.4. Asia Pacific
9.5. Rest of the World
10. COMPETITIVE LANDSCAPE
10.1. Competitor Comparison Analysis
10.2. Market Developments
10.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
10.2.2. Product Launches and execution
11. VENDOR PROFILES
11.1. Abbott Laboratories
11.1.1. Overview
11.1.2. Financial Overview
11.1.3. Product Offerings
11.1.4. Developments
11.1.5. Business Strategy
11.2. AbbVie Inc
11.2.1. Overview
11.2.2. Financial Overview
11.2.3. Product Offerings
11.2.4. Developments
11.2.5. Business Strategy
11.3. Allergan Plc
11.3.1. Overview
11.3.2. Financial Overview
11.3.3. Product Offerings
11.3.4. Developments
11.3.5. Business Strategy
11.4. GlaxoSmithKline plc
11.4.1. Overview
11.4.2. Financial Overview
11.4.3. Product Offerings
11.4.4. Developments
11.4.5. Business Strategy
11.5. Lannett Company, Inc
11.5.1. Overview
11.5.2. Financial Overview
11.5.3. Product Offerings
11.5.4. Developments
11.5.5. Business Strategy
11.6. Merck & Co. Inc
11.6.1. Overview
11.6.2. Financial Overview
11.6.3. Product Offerings
11.6.4. Developments
11.6.5. Business Strategy
11.7. Mylan N.V
11.7.1. Overview
11.7.2. Financial Overview
11.7.3. Product Offerings
11.7.4. Developments
11.7.5. Business Strategy
11.8. Novartis AG
11.8.1. Overview
11.8.2. Financial Overview
11.8.3. Product Offerings
11.8.4. Developments
11.8.5. Business Strategy
11.9. Pfizer Inc
11.9.1. Overview
11.9.2. Financial Overview
11.9.3. Product Offerings
11.9.4. Developments
11.9.5. Business Strategy
11.10. RLC LABS, Inc
11.10.1. Overview
11.10.2. Financial Overview
11.10.3. Product Offerings
11.10.4. Developments
11.10.5. Business Strategy
12. ANALYST OPINION
13. ANNEXURE
13.1. Report Scope
13.2. Market Definitions
13.3. Research Methodology
13.3.1. Data Collation and In-house Estimation
13.3.2. Market Triangulation
13.3.3. Forecasting
13.4. Report Assumptions
13.5. Declarations
13.6. Stakeholders
13.7. Abbreviations
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. DISEASE TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Hypothyroidism
5.3. Hyperthyroidism
6. DRUG TYPE: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Levothyroxine
6.3. Liothyronine
6.4. Propylthiouracil
6.5. Imidazole-based compounds
7. ROUTE OF ADMINISTRATION: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Oral
7.3. Intravenous route
8. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. Wholesaler/Distributor Retailer Mail-order Pharmacy Others
8.3. Retailer
8.4. Mail-Order Pharmacy
9. GEOGRAPHY: MARKET SIZE & ANALYSIS
9.1. Overview
9.2. North America
9.3. Europe
9.4. Asia Pacific
9.5. Rest of the World
10. COMPETITIVE LANDSCAPE
10.1. Competitor Comparison Analysis
10.2. Market Developments
10.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
10.2.2. Product Launches and execution
11. VENDOR PROFILES
11.1. Abbott Laboratories
11.1.1. Overview
11.1.2. Financial Overview
11.1.3. Product Offerings
11.1.4. Developments
11.1.5. Business Strategy
11.2. AbbVie Inc
11.2.1. Overview
11.2.2. Financial Overview
11.2.3. Product Offerings
11.2.4. Developments
11.2.5. Business Strategy
11.3. Allergan Plc
11.3.1. Overview
11.3.2. Financial Overview
11.3.3. Product Offerings
11.3.4. Developments
11.3.5. Business Strategy
11.4. GlaxoSmithKline plc
11.4.1. Overview
11.4.2. Financial Overview
11.4.3. Product Offerings
11.4.4. Developments
11.4.5. Business Strategy
11.5. Lannett Company, Inc
11.5.1. Overview
11.5.2. Financial Overview
11.5.3. Product Offerings
11.5.4. Developments
11.5.5. Business Strategy
11.6. Merck & Co. Inc
11.6.1. Overview
11.6.2. Financial Overview
11.6.3. Product Offerings
11.6.4. Developments
11.6.5. Business Strategy
11.7. Mylan N.V
11.7.1. Overview
11.7.2. Financial Overview
11.7.3. Product Offerings
11.7.4. Developments
11.7.5. Business Strategy
11.8. Novartis AG
11.8.1. Overview
11.8.2. Financial Overview
11.8.3. Product Offerings
11.8.4. Developments
11.8.5. Business Strategy
11.9. Pfizer Inc
11.9.1. Overview
11.9.2. Financial Overview
11.9.3. Product Offerings
11.9.4. Developments
11.9.5. Business Strategy
11.10. RLC LABS, Inc
11.10.1. Overview
11.10.2. Financial Overview
11.10.3. Product Offerings
11.10.4. Developments
11.10.5. Business Strategy
12. ANALYST OPINION
13. ANNEXURE
13.1. Report Scope
13.2. Market Definitions
13.3. Research Methodology
13.3.1. Data Collation and In-house Estimation
13.3.2. Market Triangulation
13.3.3. Forecasting
13.4. Report Assumptions
13.5. Declarations
13.6. Stakeholders
13.7. Abbreviations
LIST OF TABLES
TABLE 1. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 2. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR HYPOTHYROIDISM, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 3. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR HYPERTHYROIDISM, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 4. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 5. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR LEVOTHYROXINE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 6. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR LIOTHYRONINE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 7. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR PROPYLTHIOURACIL, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 8. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR IMIDAZOLE-BASED COMPOUNDS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 9. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 10. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR ORAL, 2020-2026 (USD BILLION)
TABLE 11. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR INTRAVENOUS ROUTE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 12. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 13. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR WHOLESALER/DISTRIBUTOR RETAILER MAIL-ORDER PHARMACY OTHERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 14. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR RETAILER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 15. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR MAIL-ORDER PHARMACY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 16. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 17. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 18. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 19. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 20. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 21. U.S THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 22. U.S THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 23. U.S THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 24. U.S THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 25. CANADA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 26. CANADA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 27. CANADA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 28. CANADA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 29. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 30. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 31. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 32. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 33. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 34. GERMANY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 35. GERMANY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 36. GERMANY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 37. GERMANY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 38. U.K THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 39. U.K THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 40. U.K THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 41. U.K THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 42. FRANCE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 43. FRANCE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 44. FRANCE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 45. FRANCE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 46. ITALY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 47. ITALY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 48. ITALY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 49. ITALY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 50. SPAIN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 51. SPAIN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 52. SPAIN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 53. SPAIN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 54. ROE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 55. ROE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 56. ROE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 57. ROE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 58. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 59. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 60. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 61. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 62. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 63. CHINA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 64. CHINA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 65. CHINA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 66. CHINA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 67. INDIA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 68. INDIA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 69. INDIA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 70. INDIA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 71. JAPAN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 72. JAPAN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 73. JAPAN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 74. JAPAN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 75. REST OF APAC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 76. REST OF APAC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 77. REST OF APAC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 78. REST OF APAC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 79. REST OF WORLD THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 80. REST OF WORLD THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 81. REST OF WORLD THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 82. REST OF WORLD THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 83. ABBOTT LABORATORIES: FINANCIALS
TABLE 84. ABBOTT LABORATORIES: PRODUCTS & SERVICES
TABLE 85. ABBOTT LABORATORIES: RECENT DEVELOPMENTS
TABLE 86. ABBVIE INC: FINANCIALS
TABLE 87. ABBVIE INC: PRODUCTS & SERVICES
TABLE 88. ABBVIE INC: RECENT DEVELOPMENTS
TABLE 89. ALLERGAN PLC: FINANCIALS
TABLE 90. ALLERGAN PLC: PRODUCTS & SERVICES
TABLE 91. ALLERGAN PLC: RECENT DEVELOPMENTS
TABLE 92. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 93. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES
TABLE 94. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 95. LANNETT COMPANY, INC: FINANCIALS
TABLE 96. LANNETT COMPANY, INC: PRODUCTS & SERVICES
TABLE 97. LANNETT COMPANY, INC: RECENT DEVELOPMENTS
TABLE 98. MERCK & CO. INC: FINANCIALS
TABLE 99. MERCK & CO. INC: PRODUCTS & SERVICES
TABLE 100. MERCK & CO. INC: RECENT DEVELOPMENTS
TABLE 101. MYLAN N.V: FINANCIALS
TABLE 102. MYLAN N.V: PRODUCTS & SERVICES
TABLE 103. MYLAN N.V: RECENT DEVELOPMENTS
TABLE 104. NOVARTIS AG: FINANCIALS
TABLE 105. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 106. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 107. PFIZER INC: FINANCIALS
TABLE 108. PFIZER INC: PRODUCTS & SERVICES
TABLE 109. PFIZER INC: RECENT DEVELOPMENTS
TABLE 110. RLC LABS, INC: FINANCIALS
TABLE 111. RLC LABS, INC: PRODUCTS & SERVICES
TABLE 112. RLC LABS, INC: RECENT DEVELOPMENTS
TABLE 1. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 2. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR HYPOTHYROIDISM, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 3. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR HYPERTHYROIDISM, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 4. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 5. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR LEVOTHYROXINE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 6. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR LIOTHYRONINE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 7. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR PROPYLTHIOURACIL, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 8. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR IMIDAZOLE-BASED COMPOUNDS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 9. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 10. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR ORAL, 2020-2026 (USD BILLION)
TABLE 11. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR INTRAVENOUS ROUTE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 12. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 13. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR WHOLESALER/DISTRIBUTOR RETAILER MAIL-ORDER PHARMACY OTHERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 14. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR RETAILER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 15. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR MAIL-ORDER PHARMACY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 16. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 17. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 18. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 19. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 20. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 21. U.S THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 22. U.S THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 23. U.S THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 24. U.S THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 25. CANADA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 26. CANADA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 27. CANADA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 28. CANADA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 29. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 30. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 31. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 32. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 33. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 34. GERMANY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 35. GERMANY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 36. GERMANY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 37. GERMANY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 38. U.K THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 39. U.K THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 40. U.K THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 41. U.K THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 42. FRANCE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 43. FRANCE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 44. FRANCE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 45. FRANCE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 46. ITALY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 47. ITALY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 48. ITALY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 49. ITALY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 50. SPAIN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 51. SPAIN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 52. SPAIN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 53. SPAIN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 54. ROE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 55. ROE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 56. ROE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 57. ROE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 58. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 59. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 60. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 61. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 62. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 63. CHINA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 64. CHINA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 65. CHINA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 66. CHINA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 67. INDIA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 68. INDIA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 69. INDIA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 70. INDIA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 71. JAPAN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 72. JAPAN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 73. JAPAN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 74. JAPAN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 75. REST OF APAC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 76. REST OF APAC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 77. REST OF APAC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 78. REST OF APAC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 79. REST OF WORLD THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 80. REST OF WORLD THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 81. REST OF WORLD THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 82. REST OF WORLD THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 83. ABBOTT LABORATORIES: FINANCIALS
TABLE 84. ABBOTT LABORATORIES: PRODUCTS & SERVICES
TABLE 85. ABBOTT LABORATORIES: RECENT DEVELOPMENTS
TABLE 86. ABBVIE INC: FINANCIALS
TABLE 87. ABBVIE INC: PRODUCTS & SERVICES
TABLE 88. ABBVIE INC: RECENT DEVELOPMENTS
TABLE 89. ALLERGAN PLC: FINANCIALS
TABLE 90. ALLERGAN PLC: PRODUCTS & SERVICES
TABLE 91. ALLERGAN PLC: RECENT DEVELOPMENTS
TABLE 92. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 93. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES
TABLE 94. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 95. LANNETT COMPANY, INC: FINANCIALS
TABLE 96. LANNETT COMPANY, INC: PRODUCTS & SERVICES
TABLE 97. LANNETT COMPANY, INC: RECENT DEVELOPMENTS
TABLE 98. MERCK & CO. INC: FINANCIALS
TABLE 99. MERCK & CO. INC: PRODUCTS & SERVICES
TABLE 100. MERCK & CO. INC: RECENT DEVELOPMENTS
TABLE 101. MYLAN N.V: FINANCIALS
TABLE 102. MYLAN N.V: PRODUCTS & SERVICES
TABLE 103. MYLAN N.V: RECENT DEVELOPMENTS
TABLE 104. NOVARTIS AG: FINANCIALS
TABLE 105. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 106. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 107. PFIZER INC: FINANCIALS
TABLE 108. PFIZER INC: PRODUCTS & SERVICES
TABLE 109. PFIZER INC: RECENT DEVELOPMENTS
TABLE 110. RLC LABS, INC: FINANCIALS
TABLE 111. RLC LABS, INC: PRODUCTS & SERVICES
TABLE 112. RLC LABS, INC: RECENT DEVELOPMENTS
